Skip to main content
SpringerLink
Log in

Leptomeningeal Disease and the Role of Intrathecal Therapy

  • Chapter
  • First Online:
Central Nervous System Metastases

Abstract

Leptomeningeal metastasis has been on the rise in liquid and solid malignancies and is often associated with a dismal prognosis. Multifocal neurologic signs and symptoms in patients with primary malignancies should prompt clinicians to assess for leptomeningeal metastasis. Diagnostic workup includes exam, neuroimaging, and CSF analysis along with newer diagnostic markers currently being validated and in early use. Treatment includes palliative radiation therapy and/or surgery, local or systemic chemotherapy for patients with good prognosis, and targeted therapy for those harboring identified genetic alterations. Repurposing of systemically used chemotherapeutic agents intrathecally has proven successful with few agents. New treatments are currently in trial including immune therapy, radioisotope-conjugated antibodies and growth factor, and protein fusions-targeted therapy. Characterization of the molecular phenotype of LM cancer cells is currently underway, and more work is needed to address the quantification of LM disease burden in order to better assess risk and response to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Protasoni M, Sangiorgi S, Cividini A, Culuvaris GT, Tomei G, Dell’Orbo C, et al. The collagenic architecture of human dura mater. J Neurosurg. 2011;114:1723–30.

    Article  PubMed  Google Scholar 

  2. Absinta M, Ha S-K, Nair G, Sati P, Luciano NJ, Palisoc M, et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. eLife. 2017;6:1.

    Article  Google Scholar 

  3. Balin BJ, Broadwell RD, Salcman M, el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol. 1986;251:260–80.

    Article  CAS  PubMed  Google Scholar 

  4. Yasuda K, Cline C, Vogel P, Onciu M, Fatima S, Sorrentino BP, et al. Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier. Drug Metab Dispos Biol Fate Chem. 2013;41:923–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Snyder JM, Hagan CE, Bolon B, Keene CD. 20 – Nervous system. In: Treuting PM, Dintzis SM, Montine KS, editors. Comparative anatomy and histology [Internet]. 2nd ed. San Diego: Academic; 2018. p. 403–44.. [Cited 2018 Oct 10]. Available from: http://www.sciencedirect.com/science/article/pii/B9780128029008000208.

    Chapter  Google Scholar 

  6. Hannocks M-J, Pizzo ME, Huppert J, Deshpande T, Abbott NJ, Thorne RG, et al. Molecular characterization of perivascular drainage pathways in the murine brain. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2018;38:669–86.

    Article  CAS  Google Scholar 

  7. Bedussi B, van Lier MGJTB, Bartstra JW, de Vos J, Siebes M, VanBavel E, et al. Clearance from the mouse brain by convection of interstitial fluid towards the ventricular system. Fluid Barrier CNS. 2015;12:23.

    Article  Google Scholar 

  8. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4:147ra111.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Smith AJ, Yao X, Dix JA, Jin B-J, Verkman AS. Test of the “glymphatic” hypothesis demonstrates diffusive and aquaporin-4-independent solute transport in rodent brain parenchyma. eLife. 2017;6:1.

    Google Scholar 

  10. Mestre H, Kostrikov S, Mehta RI, Nedergaard M. Perivascular spaces, glymphatic dysfunction, and small vessel disease. Clin Sci Lond Engl 1979. 2017;131:2257–74.

    CAS  Google Scholar 

  11. Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 2010;11:871–9.

    Article  CAS  PubMed  Google Scholar 

  12. Glover RL, Brook AL, Welch MR. Teaching NeuroImages: leptomeningeal lung carcinoma. Neurology. 2014;82:e183–4.

    Article  PubMed  Google Scholar 

  13. Kokkoris CP. Leptomeningeal carcinomatosis. How does cancer reach the pia-arachnoid? Cancer. 1983;51:154–60.

    Article  CAS  PubMed  Google Scholar 

  14. Boyle R, Thomas M, Adams JH. Diffuse involvement of the leptomeninges by tumour – a clinical and pathological study of 63 cases. Postgrad Med J. 1980;56:149–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Boire A, Zou Y, Shieh J, Macalinao DG, Pentsova E, Massagué J. Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell. 2017;168:1101–1113.e13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol. 1991;48:28–33.

    Article  CAS  PubMed  Google Scholar 

  17. Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med. 1991;115:507–10.

    CAS  PubMed  Google Scholar 

  18. Altundag K, Bondy ML, Mirza NQ, Kau S-W, Broglio K, Hortobagyi GN, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110:2640–7.

    Article  CAS  PubMed  Google Scholar 

  19. Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018;19:e43–55.

    Article  PubMed  Google Scholar 

  20. Dekker AW, Elderson A, Punt K, Sixma JJ. Meningeal involvement in patients with acute nonlymphocytic leukemia. Incidence, management, and predictive factors. Cancer. 1985;56:2078–82.

    Article  CAS  PubMed  Google Scholar 

  21. Peterson BA, Brunning RD, Bloomfield CD, Hurd DD, Gau JA, Peng GT, et al. Central nervous system involvement in acute nonlymphocytic leukemia. A prospective study of adults in remission. Am J Med. 1987;83:464–70.

    Article  CAS  PubMed  Google Scholar 

  22. Ersbøll J, Schultz HB, Thomsen BL, Keiding N, Nissen NI. Meningeal involvement in non-Hodgkin’s lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol. 1985;35:487–96.

    Article  PubMed  Google Scholar 

  23. Hoerni-Simon G, Suchaud JP, Eghbali H, Coindre JM, Hoerni B. Secondary involvement of the central nervous system in malignant non-Hodgkin’s lymphoma. A study of 30 cases in a series of 498 patients. Oncology. 1987;44:98–101.

    Article  CAS  PubMed  Google Scholar 

  24. Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Rehman F, et al. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neuro-Oncol. 1990;9:225–9.

    Article  CAS  Google Scholar 

  25. Rogers LR. Neurologic complications of cancer, 2nd ed. Contemp Neurol Ser Neuro-Oncol. 2009;11:96–7.

    Article  Google Scholar 

  26. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin. 2003;21:25–66.

    Article  PubMed  Google Scholar 

  27. Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010;74:1449–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hauch TW, Shelbourne JD, Cohen HJ, Mason D, Kremer WB. Meningeal mycosis fungoides: clinical and cellular characteristics. Ann Intern Med. 1975;82:499–505.

    Article  CAS  PubMed  Google Scholar 

  29. Lundberg WB, Cadman EC, Skeel RT. Leptomeningeal mycosis fungoides. Cancer. 1976;38:2149–53.

    Article  CAS  PubMed  Google Scholar 

  30. Wabulya A, Imitola J, Santagata S, Kesari S. Mycosis fungoides with leptomeningeal involvement. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:5658–61.

    Article  Google Scholar 

  31. Maldonado JE, Kyle RA, Ludwig J, Okazaki H. Meningeal myeloma. Arch Intern Med. 1970;126:660–3.

    Article  CAS  PubMed  Google Scholar 

  32. Patriarca F, Zaja F, Silvestri F, Sperotto A, Scalise A, Gigli G, et al. Meningeal and cerebral involvement in multiple myeloma patients. Ann Hematol. 2001;80:758–62.

    Article  CAS  PubMed  Google Scholar 

  33. Weed JC, Creasman WT. Meningeal carcinomatosis secondary to advanced squamous cell carcinoma of the cervix: a case report. Meningeal metastasis of advenced cervical cancer. Gynecol Oncol. 1975;3:201–4.

    Article  PubMed  Google Scholar 

  34. Barnard RO, Parsons M. Carcinoma of the thyroid with leptomeningeal dissemination following the treatment of a toxic goitre with 131-I and methyl thiouracil. Case with a co-existing intracranial dermoid. J Neurol Sci. 1969;8:299–306.

    Article  CAS  PubMed  Google Scholar 

  35. Bresalier RS, Karlin DA. Meningeal metastasis from rectal carcinoma with elevated cerebrospinal fluid carcinoembryonic antigen. Dis Colon Rectum. 1979;22:216–7.

    Article  CAS  PubMed  Google Scholar 

  36. Nagourney RA, Hedaya R, Linnoila M, Schein PS. Carcinoid carcinomatous meningitis. Ann Intern Med. 1985;102:779–82.

    Article  CAS  PubMed  Google Scholar 

  37. Berry MP, Jenkin RD. Parameningeal rhabdomyosarcoma in the young. Cancer. 1981;48:281–8.

    Article  CAS  PubMed  Google Scholar 

  38. Cash J, Fehir KM, Pollack MS. Meningeal involvement in early stage chronic lymphocytic leukemia. Cancer. 1987;59:798–800.

    Article  CAS  PubMed  Google Scholar 

  39. Matthay KK, Brisse H, Couanet D, Couturier J, Bénard J, Mosseri V, et al. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer. 2003;98:155–65.

    Article  PubMed  Google Scholar 

  40. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol. 1993;11:561–9.

    Article  CAS  PubMed  Google Scholar 

  41. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394–402.

    CAS  PubMed  Google Scholar 

  42. Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999;17:3110–6.

    Article  CAS  PubMed  Google Scholar 

  43. Hitchins RN, Bell DR, Woods RL, Levi JA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol Off J Am Soc Clin Oncol. 1987;5:1655–62.

    Article  CAS  Google Scholar 

  44. Rudnicka H, Niwinska A, Murawska M. Breast cancer leptomeningeal metastasis – the role of multimodality treatment. J Neuro-Oncol. 2007;84:57–62.

    Article  Google Scholar 

  45. Gauthier H, Guilhaume MN, Bidard FC, Pierga JY, Girre V, Cottu PH, et al. Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol. 2010;21:2183–7.

    Article  CAS  PubMed  Google Scholar 

  46. Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W, et al. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011;129:809–17.

    Article  PubMed  Google Scholar 

  47. de Azevedo CRAS, Cruz MRS, Chinen LTD, Peres SV, Peterlevitz MA, de Azevedo Pereira AE, et al. Meningeal carcinomatosis in breast cancer: prognostic factors and outcome. J Neuro-Oncol. 2011;104:565–72.

    Article  Google Scholar 

  48. Lara-Medina F, Crismatt A, Villarreal-Garza C, Alvarado-Miranda A, Flores-Hernández L, González-Pinedo M, et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J. 2012;18:233–41.

    Article  PubMed  Google Scholar 

  49. Meattini I, Livi L, Saieva C, Franceschini D, Marrazzo L, Greto D, et al. Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience. J Chemother Florence Italy. 2012;24:279–84.

    Article  Google Scholar 

  50. Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival. Med Oncol Northwood London England. 2013;30:408.

    Article  Google Scholar 

  51. Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, et al. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neuro-Oncol. 2013;114:229–35.

    Article  CAS  Google Scholar 

  52. Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, et al. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neuro-Oncol. 2013;113:83–92.

    Article  Google Scholar 

  53. Niwińska A, Rudnicka H, Murawska M. Breast cancer leptomeningeal metastasis: the results of combined treatment and the comparison of methotrexate and liposomal cytarabine as intra-cerebrospinal fluid chemotherapy. Clin Breast Cancer. 2015;15:66–72.

    Article  PubMed  CAS  Google Scholar 

  54. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2012;7:382–5.

    Google Scholar 

  55. Park JH, Kim YJ, Lee J-O, Lee K-W, Kim JH, Bang S-M, et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer Amsterdam Netherlands. 2012;76:387–92.

    Article  Google Scholar 

  56. Gwak H-S, Joo J, Kim S, Yoo H, Shin SH, Han J-Y, et al. Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2013;8:599–605.

    CAS  Google Scholar 

  57. Lee SJ, Lee J-I, Nam D-H, Ahn YC, Han JH, Sun J-M, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2013;8:185–91.

    Google Scholar 

  58. Riess JW, Nagpal S, Iv M, Zeineh M, Gubens MA, Ramchandran K, et al. Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clin Lung Cancer. 2014;15:202–6.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: a retrospective cohort analysis. Lung Cancer Amsterdam Netherlands. 2015;89:255–61.

    Article  Google Scholar 

  60. Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro-Oncology. 2008;10:1010–8.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Geukes Foppen MH, Brandsma D, Blank CU, van Thienen JV, Haanen JB, Boogerd W. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1138–42.

    Article  CAS  Google Scholar 

  62. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, et al. Leptomeningeal disease and breast cancer: the importance of tumor subtype. Breast Cancer Res Treat. 2014;146:477–86.

    Article  CAS  PubMed  Google Scholar 

  63. Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, et al. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer. 2017;17:23–8.

    Article  PubMed  Google Scholar 

  64. Clarke JL. Leptomeningeal metastasis from systemic cancer. Contin Minneap Minn. 2012;18:328–42.

    Google Scholar 

  65. Hansen K, Gjerris F, Sørensen PS. Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir. 1987;86:93–7.

    Article  CAS  PubMed  Google Scholar 

  66. Laas R, Arnold H. Compression of the outlets of the leptomeningeal veins – the cause of intracranial plateau waves. Acta Neurochir. 1981;58:187–201.

    Article  CAS  PubMed  Google Scholar 

  67. Sinniah D, Looi LM, Ortega JA, Siegel SE, Landing B. Cerebellar coning and uncal herniation in childhood acute leukaemia. Lancet Lond Engl. 1982;2:702–4.

    Article  CAS  Google Scholar 

  68. Grossman SA, Trump DL, Chen DC, Thompson G, Camargo EE. Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med. 1982;73:641–7.

    Article  CAS  PubMed  Google Scholar 

  69. Broderick JP, Cascino TL. Nonconvulsive status epilepticus in a patient with leptomeningeal cancer. Mayo Clin Proc. 1987;62:835–7.

    Article  CAS  PubMed  Google Scholar 

  70. Klein P, Haley EC, Wooten GF, VandenBerg SR. Focal cerebral infarctions associated with perivascular tumor infiltrates in carcinomatous leptomeningeal metastases. Arch Neurol. 1989;46:1149–52.

    Article  CAS  PubMed  Google Scholar 

  71. Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759–72.

    Article  CAS  PubMed  Google Scholar 

  72. Latchaw RE, Gabrielsen TO, Seeger JF. Cerebral angiography in meningeal sarcomatosis and carcinomatosis. Neuroradiology. 1974;8:131–9.

    Article  Google Scholar 

  73. Shapiro WR, Posner JB, Ushio Y, Chemik NL, Young DF. Treatment of meningeal neoplasms. Cancer Treat Rep. 1977;61:733–43.

    CAS  PubMed  Google Scholar 

  74. Lossos A, Siegal T. Numb chin syndrome in cancer patients: etiology, response to treatment, and prognostic significance. Neurology. 1992;42:1181–4.

    Article  CAS  PubMed  Google Scholar 

  75. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist. 2003;8:398–410.

    Article  PubMed  Google Scholar 

  76. Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2000;55:117–9.

    Article  CAS  PubMed  Google Scholar 

  77. Singh SK, Agris JM, Leeds NE, Ginsberg LE. Intracranial leptomeningeal metastases: comparison of depiction at FLAIR and contrast-enhanced MR imaging. Radiology. 2000;217:50–3.

    Article  CAS  PubMed  Google Scholar 

  78. Yousem DM, Patrone PM, Grossman RI. Leptomeningeal metastases: MR evaluation. J Comput Assist Tomogr. 1990;14:255–61.

    Article  CAS  PubMed  Google Scholar 

  79. Rodesch G, Avni EF, Parizel P, Detemmerman D, Szliwowski H, Brotchi J, et al. Schilder’s disease: neuroradiological findings. J Neuroradiol. 1988;15:386–93.

    CAS  PubMed  Google Scholar 

  80. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol. 1995;38:51–7.

    Article  CAS  PubMed  Google Scholar 

  81. Pan Z, Yang G, He H, Yuan T, Wang Y, Li Y, et al. Leptomeningeal metastasis from solid tumors: clinical features and its diagnostic implication. Sci Rep. 2018;8:10445.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol. 2002;23:817–21.

    PubMed  PubMed Central  Google Scholar 

  83. Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. 2017;28:iv84–99.

    Google Scholar 

  84. Bruno MK, Raizer J. Leptomeningeal metastases from solid tumors (meningeal carcinomatosis). Cancer Treat Res. 2005;125:31–52.

    Article  PubMed  Google Scholar 

  85. Bragin DE, Statom G, Nemoto EM. Dynamic cerebrovascular and intracranial pressure reactivity assessment of impaired cerebrovascular autoregulation in intracranial hypertension. Acta Neurochir Suppl. 2016;122:255–60.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Corbett JJ, Mehta MP. Cerebrospinal fluid pressure in normal obese subjects and patients with pseudotumor cerebri. Neurology. 1983;33:1386–8.

    Article  CAS  PubMed  Google Scholar 

  87. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol. 1974;30:122–37.

    Article  CAS  PubMed  Google Scholar 

  88. King DK, Loh KK, Ayala AG, Gamble JF. Letter: eosinophilic meningitis and lymphomatous meningitis. Ann Intern Med. 1975;82:228.

    Article  CAS  PubMed  Google Scholar 

  89. Mulligan MJ, Vasu R, Grossi CE, Prasthofer EF, Griffin FM, Kapila A, et al. Neoplastic meningitis with eosinophilic pleocytosis in Hodgkin’s disease: a case with cerebellar dysfunction and a review of the literature. Am J Med Sci. 1988;296:322–6.

    Article  CAS  PubMed  Google Scholar 

  90. Conrad KA, Gross JL, Trojanowski JQ. Leptomeningeal carcinomatosis presenting as eosinophilic meningitis. Acta Cytol. 1986;30:29–31.

    CAS  PubMed  Google Scholar 

  91. Budka H, Guseo A, Jellinger K, Mittermayer K. Intermittent meningitic reaction with severe basophilia and eosinophilia in CNS leukaemia. J Neurol Sci. 1976;28:459–68.

    Article  CAS  PubMed  Google Scholar 

  92. Enting RH. Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res. 2005;125:17–30.

    Article  PubMed  Google Scholar 

  93. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733–9.

    Article  CAS  PubMed  Google Scholar 

  94. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro-Oncology. 2001;3:42–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  95. De Vita VT, Canellos GP. Hypoglycorrhachia in meningeal carcinomatosis. Cancer. 1966;19:691–4.

    Article  PubMed  Google Scholar 

  96. Kim P, Ashton D, Pollard JD. Isolated hypoglycorrachia: leptomeningeal carcinomatosis causing subacute confusion. J Clin Neurosci Off J Neurosurg Soc Australas. 2005;12:841–3.

    Google Scholar 

  97. Fishman RA. Cerebrospinal fluid in diseases of the nervous system. Philadelphia: Saunders; 1992.

    Google Scholar 

  98. Bomgaars L, Chamberlain MC, Poplack DG, Blaney SM. Leptomeningeal metastases. In: Levin VA, editor. Cancer in the nervous system. 2nd ed. New York: Oxford University Press; 2002. p. 375–96.

    Google Scholar 

  99. Schold SC, Wasserstrom WR, Fleisher M, Schwartz MK, Posner JB. Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol. 1980;8:597–604.

    Article  CAS  PubMed  Google Scholar 

  100. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Mönting J, Behringer DM. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis – a single centre experience. Br J Haematol. 2004;124:762–8.

    Article  PubMed  Google Scholar 

  101. Bromberg JEC, Breems DA, Kraan J, Bikker G, van der Holt B, Smitt PS, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007;68:1674–9.

    Article  CAS  PubMed  Google Scholar 

  102. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neuro-Oncol. 2009;94:229–34.

    Article  CAS  Google Scholar 

  103. Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncology. 2012;14:689–700.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer. 1998;82:1419–42.

    Article  CAS  PubMed  Google Scholar 

  105. Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2:752–60.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, et al. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro-Oncology. 2017;19:1248–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Le Rhun E, Massin F, Tu Q, Bonneterre J, Bittencourt MDC, Faure GC. Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis. BMC Clin Pathol. 2012;12:21.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Le Rhun E, Tu Q, De Carvalho Bittencourt M, Farre I, Mortier L, Cai H, et al. Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis. Med Oncol Northwood London England. 2013;30:538.

    Article  CAS  Google Scholar 

  109. Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology. 2013;80:1598–605.. discussion 1603

    Article  PubMed  PubMed Central  Google Scholar 

  110. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467:1109–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15:559–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 2010;464:999–1005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Xie T, Cho YB, Wang K, Huang D, Hong HK, Choi Y-L, et al. Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics. 2014;104:234–41.

    Article  CAS  PubMed  Google Scholar 

  116. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461:809–13.

    Article  CAS  PubMed  Google Scholar 

  117. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123:4918–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30:413–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, et al. Mutational processes molding the genomes of 21 breast cancers. Cell. 2012;149:979–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016;34:2404–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Jaeckle KA. Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment. Semin Oncol. 2006;33:312–23.

    Article  PubMed  Google Scholar 

  122. Taillibert S, Chamberlain MC. Leptomeningeal metastasis. Handb Clin Neurol. 2018;149:169–204.

    Article  PubMed  Google Scholar 

  123. Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer. 2018;124:21–35.

    Article  PubMed  Google Scholar 

  124. Chamberlain M, Junck L, Brandsma D, Soffietti R, Rudà R, Raizer J, et al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology. 2017;19:484–92.

    Article  PubMed  CAS  Google Scholar 

  125. Joshi A, Ghosh J, Noronha V, Parikh PM, Prabhash K. Leptomeningeal metastasis in solid tumors with a special focus on lung cancer. Indian J Cancer. 2014;51:410–3.

    Article  CAS  PubMed  Google Scholar 

  126. Chang EL, Maor MH. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep. 2003;5:24–8.

    Article  PubMed  Google Scholar 

  127. Chamberlain MC, Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol. 1998;55:506–12.

    Article  CAS  PubMed  Google Scholar 

  128. Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol. 2006;13:674–81.

    Article  CAS  PubMed  Google Scholar 

  129. Bruna J, Gonzalez L, Miro J, Velasco R, Gil M, Tortosa A, et al. Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer. 2009;115:381–9.

    Article  PubMed  Google Scholar 

  130. Siegal T, Lossos A, Pfeffer MR. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology. 1994;44:1463–9.

    Article  CAS  PubMed  Google Scholar 

  131. Rubin R, Owens E, Rall D. Transport of methotrexate by the choroid plexus. Cancer Res. 1968;28:689–94.

    CAS  PubMed  Google Scholar 

  132. Fulton DS, Levin VA, Gutin PH, Edwards MS, Seager ML, Stewart J, et al. Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors. Cancer Chemother Pharmacol. 1982;8:285–91.

    Article  CAS  PubMed  Google Scholar 

  133. Esteva FJ, Soh LT, Holmes FA, Plunkett W, Meyers CA, Forman AD, et al. Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemother Pharmacol. 2000;46:382–6.

    Article  CAS  PubMed  Google Scholar 

  134. Glantz MJ, Van Horn A, Fisher R, Chamberlain MC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer. 2010;116:1947–52.

    Article  PubMed  Google Scholar 

  135. Cole BF, Glantz MJ, Jaeckle KA, Chamberlain MC, Mackowiak JI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 2003;97:3053–60.

    Article  CAS  PubMed  Google Scholar 

  136. Kim D-Y, Lee K-W, Yun T, Park SR, Jung JY, Kim D-W, et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol. 2003;33:608–12.

    Article  PubMed  Google Scholar 

  137. Gutin PH, Levi JA, Wiernik PH, Walker MD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat Rep. 1977;61:885–7.

    CAS  PubMed  Google Scholar 

  138. Comte A, Jdid W, Guilhaume MN, Kriegel I, Piperno-Neumann S, Dieras V, et al. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J Neuro-Oncol. 2013;115:445–52.

    Article  CAS  Google Scholar 

  139. Le Rhun E, Taillibert S, Devos P, Zairi F, Turpin A, Rodrigues I, et al. Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases: a retrospective case series. Anti-Cancer Drugs. 2013;24:1093–7.

    Article  PubMed  CAS  Google Scholar 

  140. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol. 1998;16:1561–7.

    Article  CAS  PubMed  Google Scholar 

  141. Tetef ML, Margolin KA, Doroshow JH, Akman S, Leong LA, Morgan RJ, et al. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother Pharmacol. 2000;46:19–26.

    Article  CAS  PubMed  Google Scholar 

  142. Boogerd W, van den Bent MJ, Koehler PJ, Heimans JJ, van der Sande JJ, Aaronson NK, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer. 2004;40:2726–33.

    Article  CAS  PubMed  Google Scholar 

  143. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol Off J Am Soc Clin Oncol. 1983;1:546–51.

    Article  CAS  Google Scholar 

  144. Lopez JA, Nassif E, Vannicola P, Krikorian JG, Agarwal RP. Central nervous system pharmacokinetics of high-dose cytosine arabinoside. J Neuro-Oncol. 1985;3:119–24.

    Article  CAS  Google Scholar 

  145. Siegal T. Leptomeningeal metastases: rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? J Neuro-Oncol. 1998;38:151–7.

    Article  CAS  Google Scholar 

  146. Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer. 1998;82:1756–63.

    Article  CAS  PubMed  Google Scholar 

  147. Shigekawa T, Takeuchi H, Misumi M, Matsuura K, Sano H, Fujiuchi N, et al. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. Breast Cancer. 2009;16:88–92.

    Article  PubMed  Google Scholar 

  148. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neuro-Oncol. 2007;85:223–7.

    Article  CAS  Google Scholar 

  149. Davis TH, Fadul CE, Glantz MJ, et al. Pilot phase II trial of temozolomide for leptomeningeal metastases: preliminary report. J Clin Oncol. 2003;22:460.

    Google Scholar 

  150. Herrlinger U, Wiendl H, Renninger M, Forschler H, Dichgans J, Weller M. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer. 2004;91:219–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Reijneveld JC, Brandsma D, Boogerd W, Bonfrer JG, Kalmijn S, Voest EE, et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology. 2005;65:1120–2.

    Article  CAS  PubMed  Google Scholar 

  152. Reijneveld JC, Taphoorn MJ, Kerckhaert OA, Drixler TA, Boogerd W, Voest EE. Angiostatin prolongs the survival of mice with leptomeningeal metastases. Eur J Clin Investig. 2003;33:76–81.

    Article  CAS  Google Scholar 

  153. Chen IC, Lin CH, Jan IS, Cheng AL, Lu YS. Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis. J Formos Med Assoc. 2016;115:243–8.

    Article  CAS  PubMed  Google Scholar 

  154. Wu PF, Lin CH, Kuo CH, Chen WW, Yeh DC, Liao HW, et al. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer. 2015;15:299.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  155. Groves MD. A pilot study of systemically administeres bevacizumab in patients with neoplastic maningitis: imaging, clinical, CSF, and biomarker outcomes. Neuro-Oncology. 2011;13:85–91.

    Google Scholar 

  156. Simeone E, De Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, et al. Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep. 2012;6:131.

    Article  PubMed  PubMed Central  Google Scholar 

  157. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet London England. 2015;386:444–51.

    Article  CAS  Google Scholar 

  158. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.

    Article  PubMed  CAS  Google Scholar 

  159. Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248–60.

    Article  CAS  PubMed  Google Scholar 

  160. Yi HG, Kim HJ, Kim YJ, Han S-W, Oh D-Y, Lee S-H, et al. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI. Lung Cancer Amsterdam Netherlands. 2009;65:80–4.

    Article  Google Scholar 

  161. Dhruva N, Socinski MA. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:e31–2.

    Article  Google Scholar 

  162. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neuro-Oncol. 2010;99:283–6.

    Article  Google Scholar 

  163. Cessot A, Blanchet B, Goldwasser F. Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:2093–4.

    Article  CAS  Google Scholar 

  164. Kawamura T, Hata A, Takeshita J, Fujita S, Hayashi M, Tomii K, et al. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs. Cancer Chemother Pharmacol. 2015;75:1261–6.

    Article  CAS  PubMed  Google Scholar 

  165. Kanaji N, Bandoh S, Nagamura N, Kushida Y, Haba R, Ishida T. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. Intern Med Tokyo Japan. 2007;46:1651–5.

    Article  Google Scholar 

  166. Sakai M, Ishikawa S, Ito H, Ozawa Y, Yamamoto T, Onizuka M, et al. Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib. Int J Clin Oncol. 2006;11:243–5.

    Article  PubMed  Google Scholar 

  167. Hashimoto N, Imaizumi K, Honda T, Kawabe T, Nagasaka T, Shimokata K, et al. Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer Amsterdam Netherlands. 2006;53:387–90.

    Article  Google Scholar 

  168. So T, Inoue M, Chikaishi Y, Nose N, Sugio K, Yasumoto K. Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases. Surg Today. 2009;39:598–602.

    Article  PubMed  Google Scholar 

  169. Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:4517–20.

    Article  Google Scholar 

  170. Burel-Vandenbos F, Ambrosetti D, Coutts M, Pedeutour F. EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neuro-Oncol. 2013;111:1–10.

    Article  CAS  Google Scholar 

  171. Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:89–99.

    Article  CAS  Google Scholar 

  172. Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schütz M, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10:156–63.

    CAS  Google Scholar 

  173. Tamiya M, Shiroyama T, Nishihara T, Nishida T, Hayama M, Tanaka A, et al. Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy. Asia Pac J Clin Oncol. 2017;13:e531–3.

    Article  PubMed  Google Scholar 

  174. Lin C-H, Lin M-T, Kuo Y-W, Ho C-C. Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis. Lung Cancer Amsterdam Netherlands. 2014;85:479–80.

    Article  Google Scholar 

  175. Yang JC-H, Cho BC, Kim D-W, Kim S-W, Lee J-S, Su W-C, et al. Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): updated results from the BLOOM study. J Clin Oncol. 2017;35:2020.

    Article  Google Scholar 

  176. Ahn M-J, Kim D-W, Cho BC, Kim S-W, Lee JS, Ahn J-S, et al. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017;5:891–902.

    Article  CAS  PubMed  Google Scholar 

  177. Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15:1119–28.

    Article  CAS  PubMed  Google Scholar 

  178. Gainor JF, Chi AS, Logan J, Hu R, Oh KS, Brastianos PK, et al. Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11:256–60.

    Google Scholar 

  179. Gainor JF, Sherman CA, Willoughby K, Logan J, Kennedy E, Brastianos PK, et al. Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10:232–6.

    CAS  Google Scholar 

  180. Ou S-HI, Sommers KR, Azada MC, Garon EB. Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. Oncologist. 2015;20:224–6.

    Article  PubMed  PubMed Central  Google Scholar 

  181. Roth P, Weller M. Management of neoplastic meningitis. Chin Clin Oncol. 2015;4:26.

    PubMed  Google Scholar 

  182. Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. 2012;13:e375–82.

    Article  PubMed  Google Scholar 

  183. Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672–81.

    Article  CAS  PubMed  Google Scholar 

  184. Chamberlain MC. A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer. 2002;94:2675–80.

    Article  CAS  PubMed  Google Scholar 

  185. Ward BG, Cruickshank DJ. Circulating tumor-associated antigen detected by the monoclonal antibody HMFG2 in human epithelial ovarian cancer. Int J Cancer. 1987;39:30–3.

    Article  CAS  PubMed  Google Scholar 

  186. Moseley RP, Papanastassiou V, Zalutsky MR, Ashpole RD, Evans S, Bigner DD, et al. Immunoreactivity, pharmacokinetics and bone marrow dosimetry of intrathecal radioimmunoconjugates. Int J Cancer. 1992;52:38–43.

    Article  CAS  PubMed  Google Scholar 

  187. Kramer K, Humm JL, Souweidane MM, Zanzonico PB, Dunkel IJ, Gerald WL, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:5465–70.

    Article  Google Scholar 

  188. Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neuro-Oncol. 2010;97:409–18.

    Article  Google Scholar 

  189. Slavc I, Schuller E, Falger J, Günes M, Pillwein K, Czech T, et al. Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors. J Neuro-Oncol. 2003;64:239–47.

    Article  Google Scholar 

  190. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet. 2005;44:1–31.

    Article  PubMed  Google Scholar 

  191. Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. 2006;106:2021–7.

    Article  CAS  PubMed  Google Scholar 

  192. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology. 2008;10:208–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:1540–6.

    Article  CAS  Google Scholar 

  194. Friedman HS, Archer GE, McLendon RE, Schuster JM, Colvin OM, Guaspari A, et al. Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. Cancer Res. 1994;54:4710–4.

    CAS  PubMed  Google Scholar 

  195. Kochi M, Kuratsu J, Mihara Y, Takaki S, Inoue N, Sueyoshi N, et al. Neurotoxicity and pharmacokinetics of intrathecal perfusion of ACNU in dogs. Cancer Res. 1990;50:3119–23.

    CAS  PubMed  Google Scholar 

  196. Champagne MA, Silver HK. Intrathecal dacarbazine treatment of leptomeningeal malignant melanoma. J Natl Cancer Inst. 1992;84:1203–4.

    Article  CAS  PubMed  Google Scholar 

  197. Cordone I, Masi S, Summa V, Carosi M, Vidiri A, Fabi A, et al. Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study. Breast Cancer Res BCR. 2017;19:46.

    Article  PubMed  CAS  Google Scholar 

  198. Gold DR, Nadel RE, Vangelakos CG, Davis MJ, Livingston MY, Heath JE, et al. Pearls and oy-sters: the utility of cytology and flow cytometry in the diagnosis of leptomeningeal leukemia. Neurology. 2013;80:e156–9.

    Article  PubMed  Google Scholar 

  199. Subirá D, Serrano C, Castañón S, Gonzalo R, Illán J, Pardo J, et al. Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. Neuro-Oncology. 2012;14:43–52.

    Article  PubMed  Google Scholar 

  200. Subirá D, Simó M, Illán J, Serrano C, Castañón S, Gonzalo R, et al. Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. Clin Exp Metastasis. 2015;32:383–91.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Fadi Saadeh

  2. Human Oncogenesis and Pathology Program, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Adrienne Boire

Authors
  1. Fadi Saadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adrienne Boire
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrienne Boire .

Editor information

Editors and Affiliations

  1. Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, Director - Brain Metastases Program, New York, NY, USA

    Rohan Ramakrishna

  2. Department of Neurology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Rajiv S. Magge

  3. Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Ali A. Baaj

  4. Department of Radiation Oncology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Jonathan P.S. Knisely

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Saadeh, F., Boire, A. (2020). Leptomeningeal Disease and the Role of Intrathecal Therapy. In: Ramakrishna, R., Magge, R., Baaj, A., Knisely, J. (eds) Central Nervous System Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-42958-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-42958-4_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-42957-7

  • Online ISBN: 978-3-030-42958-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation